Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

Kimberly M. Brown, Veeriah Siripurapu, Marson Davidson, Steven J. Cohen, Andre Konski, James C. Watson, Tiaynu Li, Vince Ciocca, Harry Cooper, John P. Hoffman

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: For patients with borderline resectable pancreatic cancer, preoperative chemoradiation and standalone chemotherapy may allow for R0 resection and improved survival. Methods: A retrospective review of patients with borderline resectable pancreatic cancer treated with preoperative chemoradiation and standalone chemotherapy was undertaken. Clinical variables, including disease-free and overall survival, were collected. Univariate analysis was used to identify factors impacting survival. Results: Thirteen patients with borderline resectable pancreatic cancer were treated with preoperative chemoradiation and chemotherapy. Morbidity and mortality were 38% and 0. There were 2 R1 and 11 R0 resections. Nine patients are alive with a median follow-up of 20 months. Five patients recurred at a median of 4 months. Tumor fibrosis ≤60% was associated with recurrence and poor survival. Conclusions: Preoperative chemoradiation and chemotherapy allow a select group of patients with borderline resectable pancreatic cancer to undergo an R0 or R1 resection with acceptable morbidity and mortality. Tumor response may be associated with survival.

Original languageEnglish (US)
Pages (from-to)318-321
Number of pages4
JournalAmerican Journal of Surgery
Volume195
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Adenocarcinoma
Pancreatic Neoplasms
Drug Therapy
Survival
Morbidity
Mortality
Disease-Free Survival
Neoplasms
Fibrosis
Recurrence

Keywords

  • Borderline resectable
  • Cancer
  • Chemoradiation
  • Chemotherapy
  • Neoadjuvant
  • Pancreas
  • Pancreatic cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Brown, K. M., Siripurapu, V., Davidson, M., Cohen, S. J., Konski, A., Watson, J. C., ... Hoffman, J. P. (2008). Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. American Journal of Surgery, 195(3), 318-321. https://doi.org/10.1016/j.amjsurg.2007.12.017

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. / Brown, Kimberly M.; Siripurapu, Veeriah; Davidson, Marson; Cohen, Steven J.; Konski, Andre; Watson, James C.; Li, Tiaynu; Ciocca, Vince; Cooper, Harry; Hoffman, John P.

In: American Journal of Surgery, Vol. 195, No. 3, 03.2008, p. 318-321.

Research output: Contribution to journalArticle

Brown, KM, Siripurapu, V, Davidson, M, Cohen, SJ, Konski, A, Watson, JC, Li, T, Ciocca, V, Cooper, H & Hoffman, JP 2008, 'Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma', American Journal of Surgery, vol. 195, no. 3, pp. 318-321. https://doi.org/10.1016/j.amjsurg.2007.12.017
Brown, Kimberly M. ; Siripurapu, Veeriah ; Davidson, Marson ; Cohen, Steven J. ; Konski, Andre ; Watson, James C. ; Li, Tiaynu ; Ciocca, Vince ; Cooper, Harry ; Hoffman, John P. / Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. In: American Journal of Surgery. 2008 ; Vol. 195, No. 3. pp. 318-321.
@article{f2b167e394914a3ba3e609a32a0fcc4f,
title = "Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma",
abstract = "Background: For patients with borderline resectable pancreatic cancer, preoperative chemoradiation and standalone chemotherapy may allow for R0 resection and improved survival. Methods: A retrospective review of patients with borderline resectable pancreatic cancer treated with preoperative chemoradiation and standalone chemotherapy was undertaken. Clinical variables, including disease-free and overall survival, were collected. Univariate analysis was used to identify factors impacting survival. Results: Thirteen patients with borderline resectable pancreatic cancer were treated with preoperative chemoradiation and chemotherapy. Morbidity and mortality were 38{\%} and 0. There were 2 R1 and 11 R0 resections. Nine patients are alive with a median follow-up of 20 months. Five patients recurred at a median of 4 months. Tumor fibrosis ≤60{\%} was associated with recurrence and poor survival. Conclusions: Preoperative chemoradiation and chemotherapy allow a select group of patients with borderline resectable pancreatic cancer to undergo an R0 or R1 resection with acceptable morbidity and mortality. Tumor response may be associated with survival.",
keywords = "Borderline resectable, Cancer, Chemoradiation, Chemotherapy, Neoadjuvant, Pancreas, Pancreatic cancer",
author = "Brown, {Kimberly M.} and Veeriah Siripurapu and Marson Davidson and Cohen, {Steven J.} and Andre Konski and Watson, {James C.} and Tiaynu Li and Vince Ciocca and Harry Cooper and Hoffman, {John P.}",
year = "2008",
month = "3",
doi = "10.1016/j.amjsurg.2007.12.017",
language = "English (US)",
volume = "195",
pages = "318--321",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

AU - Brown, Kimberly M.

AU - Siripurapu, Veeriah

AU - Davidson, Marson

AU - Cohen, Steven J.

AU - Konski, Andre

AU - Watson, James C.

AU - Li, Tiaynu

AU - Ciocca, Vince

AU - Cooper, Harry

AU - Hoffman, John P.

PY - 2008/3

Y1 - 2008/3

N2 - Background: For patients with borderline resectable pancreatic cancer, preoperative chemoradiation and standalone chemotherapy may allow for R0 resection and improved survival. Methods: A retrospective review of patients with borderline resectable pancreatic cancer treated with preoperative chemoradiation and standalone chemotherapy was undertaken. Clinical variables, including disease-free and overall survival, were collected. Univariate analysis was used to identify factors impacting survival. Results: Thirteen patients with borderline resectable pancreatic cancer were treated with preoperative chemoradiation and chemotherapy. Morbidity and mortality were 38% and 0. There were 2 R1 and 11 R0 resections. Nine patients are alive with a median follow-up of 20 months. Five patients recurred at a median of 4 months. Tumor fibrosis ≤60% was associated with recurrence and poor survival. Conclusions: Preoperative chemoradiation and chemotherapy allow a select group of patients with borderline resectable pancreatic cancer to undergo an R0 or R1 resection with acceptable morbidity and mortality. Tumor response may be associated with survival.

AB - Background: For patients with borderline resectable pancreatic cancer, preoperative chemoradiation and standalone chemotherapy may allow for R0 resection and improved survival. Methods: A retrospective review of patients with borderline resectable pancreatic cancer treated with preoperative chemoradiation and standalone chemotherapy was undertaken. Clinical variables, including disease-free and overall survival, were collected. Univariate analysis was used to identify factors impacting survival. Results: Thirteen patients with borderline resectable pancreatic cancer were treated with preoperative chemoradiation and chemotherapy. Morbidity and mortality were 38% and 0. There were 2 R1 and 11 R0 resections. Nine patients are alive with a median follow-up of 20 months. Five patients recurred at a median of 4 months. Tumor fibrosis ≤60% was associated with recurrence and poor survival. Conclusions: Preoperative chemoradiation and chemotherapy allow a select group of patients with borderline resectable pancreatic cancer to undergo an R0 or R1 resection with acceptable morbidity and mortality. Tumor response may be associated with survival.

KW - Borderline resectable

KW - Cancer

KW - Chemoradiation

KW - Chemotherapy

KW - Neoadjuvant

KW - Pancreas

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=40749098149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749098149&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2007.12.017

DO - 10.1016/j.amjsurg.2007.12.017

M3 - Article

VL - 195

SP - 318

EP - 321

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 3

ER -